ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 8 for:    maytin

Vitamin D as a Nutritional Neoadjuvant During Photodynamic Therapy of Basal Cell Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03467789
Recruitment Status : Recruiting
First Posted : March 16, 2018
Last Update Posted : December 6, 2018
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Case Comprehensive Cancer Center

Brief Summary:

The purpose of this study is to study 50 patients with multiple Basal Cell Carcinoma (BCC) who will be receiving Photodynamic Therapy (PDT) as treatment for their tumors. This study wants to establish the optimal conditions for treating BCC tumors with PDT. Previous research suggests that taking Vitamin D prior to the start of PDT could help improve the effectiveness of the treatment in eliminating the BCC. Overall, this study will help establish oral Vitamin D3/PDT as a new combination therapy for skin cancer (BCC).

Photodynamic Therapy (PDT) is an investigational (experimental) technique that works by combining a photosensitizing topical agent and an intense light source to kill tumor cells. PDT is currently approved for the treatment of BCC in Europe, Canada, and Australia. However, it is experimental in the United States because it is not approved by the Food and Drug Administration (FDA).


Condition or disease Intervention/treatment Phase
Basal Cell Carcinoma Basal Cell Nevus Syndrome Dietary Supplement: Vitamin D3 prior to first visit Dietary Supplement: Vitamin D3 prior to second visit Radiation: Photodynamic therapy Dietary Supplement: Maintenance Vitamin D3 Not Applicable

Detailed Description:

The overall hypothesis is that PDT could provide exceptional benefit in patients with Basal Cell Nevus Syndrome (BCNS) and multiple BCC tumors because PDT is nonmutagenic, nonscarring, and can be safely repeated many times. The specific study hypothesis is that Vitamin D might be useful as a neoadjuvant to improve tumor responses to PDT. In preclinical studies, the investigators showed that epithelial tumors are more responsive to aminolevulinic acid (ALA)-based PDT when "primed" by pre-exposure to the dietary form of Vitamin D (cholecalciferol, D3). This study will test the hypothesis that oral D3 supplements, administered over a relatively short time, can boost the effectiveness of PDT for cutaneous (BCC) in this patient population. Patients with BCNS and multiple BCC, or normal patients with at least 3 BCC tumors, will be enrolled. They will receive three PDT treatments, at two-month intervals, over a 6 month period.

Primary Objective

• To determine tumor clinical clearance rates after neoadjuvant D3/PDT, and after PDT alone. To accomplish this, the first two PDT treatments in each study patient will be randomized, i.e. one PDT session will be performed after D3 pretreatment, the other without any pretreatment.

Secondary Objective(s)

  • To assess the level of PpIX accumulation in BCC lesions at various treatment visits, in the absence or presence of neoadjuvant D3. (Fluorescence dosimetry measurements)
  • To assess tolerability of the technique. (Pain scale measurements)
  • To assess patient satisfaction with the technique. (Cosmetic result, and questionnaire)
  • To assess D3 serum levels (in serum) and VDR status (in leukocyte DNA), and correlate these results to clinical outcomes.

Study Design:

In this clinical study, each patient will serve as his or her own control with respect to BCC tumor responsiveness to neoadjuvant D3 supplementation. The first two PDT treatments will be randomized. Thus, patients in Group A will take D3 pills prior to the first PDT treatment, and placebo pills prior to the second PDT treatment. For patients in Group B, the order is reversed. Total amounts of D3 supplementation given will be adjusted, based upon serum 25-hydroxy-D3 levels found at baseline. Patients with VD deficiency will take 14 days of neoadjuvant D3, vs. only 5 days if the initial VD level is normal.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Care Provider)
Masking Description: The study will be double-blinded. Neither the patient nor the treating physicians will know which patients receive the Vitamin D3 or placebo pills. Using a "coin toss" approach, the Research Pharmacist will assign each patient to a study group
Primary Purpose: Treatment
Official Title: Vitamin D as a Nutritional Neoadjuvant During Photodynamic Therapy of Basal Cell Carcinoma in Basal Cell Nevus Syndrome
Actual Study Start Date : October 1, 2018
Estimated Primary Completion Date : November 2021
Estimated Study Completion Date : November 2021


Arm Intervention/treatment
Experimental: Group A: D3 prior to first PDT
Group A will take D3 pills prior to the first PDT treatment, and placebo pills prior to the second PDT treatment. Both Group A and Group B will take no study drug prior to their third PDT visit.
Dietary Supplement: Vitamin D3 prior to first visit
The daily dose of D3 will always be 10,000 IU/day. Total amounts of D3 supplementation given will be adjusted, based upon serum 25-hydroxy-D3 levels found at baseline. Patients with VD deficiency will take 14 days of neoadjuvant D3, vs. only 5 days if the initial VD level is normal.

Radiation: Photodynamic therapy
Photodynamic Therapy (PDT) is an experimental technique that works by combining a photosensitizing topical agent and an intense light source to kill tumor cells.
Other Name: PDT

Dietary Supplement: Maintenance Vitamin D3
2,000 IU/d for adults, 1,000 IU/d for children taken after third visit.

Experimental: Group B: D3 prior to second PDT visit
GROUP B will receive placebo prior to their first PDT visit, and Vitamin D3 prior to their second PDT visit. Both Group A and Group B will take no study drug prior to their third PDT visit.
Dietary Supplement: Vitamin D3 prior to second visit
The daily dose of D3 will always be 10,000 IU/day. Total amounts of D3 supplementation given will be adjusted, based upon serum 25-hydroxy-D3 levels found at baseline. Patients with VD deficiency will take 14 days of neoadjuvant D3, vs. only 5 days if the initial VD level is normal.

Radiation: Photodynamic therapy
Photodynamic Therapy (PDT) is an experimental technique that works by combining a photosensitizing topical agent and an intense light source to kill tumor cells.
Other Name: PDT

Dietary Supplement: Maintenance Vitamin D3
2,000 IU/d for adults, 1,000 IU/d for children taken after third visit.




Primary Outcome Measures :
  1. Rate of tumor clearance [ Time Frame: Up to 6 months after first treatment visit ]
    Change in tumor diameter per month. The statistical significance of the difference in Delta-T after D3+PDT versus the difference in Delta-T after PDT alone will be tested using ANOVA.


Secondary Outcome Measures :
  1. Level of protoporphyrin IX (PpIX) accumulation in BCC lesions, in the presence of neoadjuvant D3 [ Time Frame: Up to 6 months after first treatment visit ]
    Fluorescence dosimetry measurements of PpIX photo absorption with Vitamin D3

  2. Level of protoporphyrin IX (PpIX) accumulation in BCC lesions, in the absence of neoadjuvant D3 [ Time Frame: Up to 6 months after first treatment visit ]
    Fluorescence dosimetry measurements of PpIX photo absorption without Vitamin D3

  3. Serum 25-hydroxy-vitamin D3 (25OH-D3) levels [ Time Frame: Up to 6 months after first treatment visit ]
    Using a 10mL blood sample, a 25OH-D3 assay will be used to determine D3 levels in the blood

  4. Number of patients with active form of leukocyte DNA vitamin D Receptor (VDR) [ Time Frame: Up to 6 months after first treatment visit ]
    Study team will collect patients' leukocyte DNA and examine the VDR gene sequences directly. Patients with the active VDR allele are postulated to have better PDT outcomes

  5. Pain scale measurement [ Time Frame: Up to 6 months after first treatment visit ]
    average pain scale measurements to assess tolerability of the technique. Ranging from 0 to 10 where 0 indicates no pain and 10 indicates the worst pain possible

  6. Number of patient symptoms [ Time Frame: Up to 6 months after first treatment visit ]
    A measure of Patient Satisfaction Score. Number of symptoms reported by patients in the week following PDT treatment

  7. Erythema score [ Time Frame: Up to 6 months after first treatment visit ]
    A measure of Patient Satisfaction Score. Score from photographs on a scale from 1-4 with higher scores indicating more erythema



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • diagnosis of Basal Cell Nevus Syndrome (BCNS) as defined in the Consensus Statement from the first International colloquium on BCNS.

    • Major Criteria are:

      • (1) BCC prior to age 20 years, or excessive number of BCCs out of proportion to prior sun exposure and skin type;
      • (2) keratocyst of the jaw prior to age 20;
      • (3) palmar or plantar pitting;
      • (4) lamellar calcification of the falx cerebri;
      • (5) medulloblastoma;
      • (6) first degree relative with BCNS;
      • (7) Patched-1 (PTCH1) gene mutation.
    • Minor Criteria are:

      • (1) rib anomalies, or other specific skeletal malformations including kyphoscoliosis and short 4th metacarpals;
      • (2) macrocephaly;
      • (3) cleft/lip or palate;
      • (4) fibroma of the heart or ovary;
      • (5) ocular abnormalities;
    • For diagnosis of BCNS, the patient must have either 2 major criteria, one major and two minor criteria.
  • At least three BCC tumors, two of which are biopsy-proven
  • Female subjects must not become pregnant during the study
  • Subjects must be able to understand and willing to sign a written informed consent document

Exclusion Criteria:

  • Pregnant or nursing.
  • At risk for hypercalcemia (renal disease, sarcoidosis, etc.)
  • Taking vismodegib or a hedgehog pathway inhibitor; must stop at least 1 month prior.
  • Taking any topical treatment on their BCC tumors; must stop at least one month prior.
  • Taking Vitamin D or multivitamin supplements; must stop at least one month prior.
  • Currently undergoing treatment for other cancers with medical or radiation therapy.
  • Patients with a known hypersensitivity to 5-aminolevulinic acid or any component of the study material.
  • Patients with history of a photosensitivity disease, such as porphyria cutanea tarda.
  • Currently participating in another clinical trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03467789


Contacts
Contact: Edward V. Maytin, MD, PhD 216-445-6676 maytine@ccf.org

Locations
United States, Ohio
Cleveland Clinic, Case Comprehensive Cancer Center Recruiting
Cleveland, Ohio, United States, 44195
Contact: Edward Maytin, MD, PhD    216-445-6676    maytine@ccf.org   
Principal Investigator: Edward Maytin, MD, PhD         
Sponsors and Collaborators
Case Comprehensive Cancer Center
National Cancer Institute (NCI)
Investigators
Principal Investigator: Edward V. Maytin, MD, PhD Cleveland Clinic, Case Comprehensive Cancer Center

Responsible Party: Case Comprehensive Cancer Center
ClinicalTrials.gov Identifier: NCT03467789     History of Changes
Other Study ID Numbers: CASE5617
First Posted: March 16, 2018    Key Record Dates
Last Update Posted: December 6, 2018
Last Verified: December 2018

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: No
Pediatric Postmarket Surveillance of a Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by Case Comprehensive Cancer Center:
Vitamin D
Photodynamic Therapy

Additional relevant MeSH terms:
Syndrome
Carcinoma
Carcinoma, Basal Cell
Basal Cell Nevus Syndrome
Disease
Pathologic Processes
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Basal Cell
Odontogenic Cysts
Jaw Cysts
Bone Cysts
Cysts
Neoplastic Syndromes, Hereditary
Bone Diseases, Developmental
Bone Diseases
Musculoskeletal Diseases
Jaw Diseases
Stomatognathic Diseases
Abnormalities, Multiple
Congenital Abnormalities
Genetic Diseases, Inborn
Vitamins
Vitamin D
Ergocalciferols
Cholecalciferol
Micronutrients
Growth Substances
Physiological Effects of Drugs